The present invention relates to cannabigerol (CBG), a cannabinoid, for use in the treatment of chronic insomnia, sleeplessness and ''staying in sleep'' discomfort, subjective and objective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and/or hyperactivity. The invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid Cannabinodiol (CBND) for use in the treatment of chronic insomnia, sleeplessness and ''staying in sleep'' discomfort, subjective and objective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and/or hyperactivity, preferably wherein the ratio of CBG: CBND by weight is between 10:1 and1:10. The invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid tetrahydrocannabinol (THC) for use in thetreatmentofchronic insomnia, sleeplessness and ''stayingin sleep'' discomfort, subjective andobjective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and/or hyperactivity. The present invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG)and cannabinoid tetrahydrocannabinol (THC) for usein the treatment of depression as anti-depressive and aremedy for a depressive mood, preferably wherein the ratio of CBG: THC by weight isbetween 10:1 and 1:10,more preferably between 1:5 and 5:1. The present invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid tetrahydrocannabinol (THC) for use as mood stabilizer and relaxator,preferably wherein the ratio of CBG: THC by weight is between 7:3and 3:7,more preferably between 2:5 and 5:2.La présente invention concerne un cannabinoïde, le Cannabigérol (CBG), destiné à être utilisé dans le traitement de l'insomnie chronique, du malaise provoqué par l'i
